Schimmelpennink MC, et al. - The efficacy and safety of Inflectra (a less expensive biosimilar of infliximab) in sarcoidosis, was assessed. As a treatment option for refractory sarcoidosis, infliximab biosimilar Inflectra seemed effective. Its safety profile was comparable to the reference product Remicade. Overall, Inflectra can be considered as an alternative and less expensive option for patients with refractory sarcoidosis.